Media headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.7174280516513 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- BioMarin Pharmaceutical’s (BMRN) “Buy” Rating Reaffirmed at Piper Jaffray Companies (americanbankingnews.com)
- $347.03 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter (americanbankingnews.com)
- Zacks Investment Research Downgrades BioMarin Pharmaceutical (BMRN) to Hold (americanbankingnews.com)
- Zacks: Analysts Expect BioMarin Pharmaceutical Inc. (BMRN) to Announce -$0.24 EPS (americanbankingnews.com)
A number of research firms recently commented on BMRN. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Goldman Sachs Group reissued a “buy” rating and set a $129.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $117.00 target price (up previously from $115.00) on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Jefferies Group reaffirmed a “buy” rating and issued a $116.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, September 26th. Finally, BidaskClub raised shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, December 16th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $111.69.
Shares of BioMarin Pharmaceutical (BMRN) traded up $0.14 on Thursday, reaching $89.78. 1,166,909 shares of the company’s stock were exchanged, compared to its average volume of 1,279,833. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $15,770.00, a PE ratio of -108.17 and a beta of 1.81. BioMarin Pharmaceutical has a one year low of $80.10 and a one year high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $334.18 million during the quarter, compared to the consensus estimate of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The company’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.02 earnings per share. research analysts predict that BioMarin Pharmaceutical will post -0.64 earnings per share for the current fiscal year.
In related news, Director Elaine J. Heron sold 800 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $88.90, for a total value of $71,120.00. Following the completion of the sale, the director now directly owns 38,385 shares in the company, valued at $3,412,426.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $90.32, for a total transaction of $903,200.00. Following the completion of the sale, the chief executive officer now owns 235,894 shares of the company’s stock, valued at $21,305,946.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,750 shares of company stock valued at $5,439,788. Insiders own 1.85% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.truebluetribune.com/2018/01/19/biomarin-pharmaceutical-bmrn-earns-news-sentiment-rating-of-0-19.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.